866-997-4948(US-Canada Toll Free)

Obstetrics Partnering Terms and Agreements

Published By :

Current Partnering

Published Date : Feb 2014

Category :

Biotechnology

No. of Pages : 428 Pages

The Obstetrics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the obstetrics partnering deals and agreements entered into by the worlds leading healthcare companies.
 
The report provides a detailed understanding and analysis of how and why companies enter obstetrics partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors obstetrics technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
 
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.
                                
This report contains over 500 links to online copies of actual obstetrics deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
 
The initial chapters of this report provide an orientation of obstetrics dealmaking and business activities. 

Chapter 1 provides an introduction to the report.
 
Chapter 2 provides an overview of the trends in obstetrics dealmaking since 2009 covering trends by year, deal type, stage of development, technology type and therapeutic indication. In addition the chapter includes an analysis of financial deal terms by stage at signing covering headline value, upfront payment, milestone payments and royalty rates. Analysis includes median values and distribution of values for each stage of development.
                             
Chapter 3 provides a review of the leading obstetrics deals since 2009. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
 
Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of obstetrics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
 
Chapter 5 provides comprehensive access to all obstetrics deals since 2009 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.
 
Chapter 6 provides a comprehensive directory of all obstetrics partnering deals signed and announced since 2009. The chapter is organized by specific obstetrics therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
 
In addition, a comprehensive appendix is provided with each report of all obstetrics partnering deals signed and announced since 2009. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
 
The report also includes numerous tables and figures that illustrate the trends and activities in obstetrics partnering and dealmaking since 2009.
                                                  
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of obstetrics technologies and products.

Obstetrics Partnering Terms and Agreements provides the reader with the following key benefits:
 
  • In-depth understanding of obstetrics  deal trends since 2009
  • Access obstetrics deal headline, upfront, milestone and royalty data
  • Research hundreds of actual contracts between obstetrics partner companies
  • Comprehensive access to over 500 links to actual obstetrics deals entered into by the world’s biopharma companies
  • Indepth review of obstetrics deals entered into by the leading fifty bigpharma companies
  • Benchmark the key deal terms companies have agreed in previous deals          
  • Identify key terms under which companies partner obstetrics opportunities
  • Uncover companies actively partnering obstetrics opportunities
 
Report scope
                            
Obstetrics Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to pediatrics trends and structure of deals entered into by leading companies worldwide.
                                     
Obstetrics Partnering Terms and Agreements includes:
                                                        
  • Trends in obstetrics dealmaking in the biopharma industry since 2009
  • Analysis of obstetrics deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to hundreds of obstetrics deal contract documents
  • Comprehensive access to over 500 obstetrics deal records
  • The leading obstetrics deals by value since 2009
  • Most active obstetrics dealmakers since 2009                                                        
 In Obstetrics Partnering Terms and Agreements, available deals and contracts are listed by:
 
  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Stage of development at signing
  • Deal component type
  • Technology type
  • Specific therapy indication
Table of Content

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in obstetrics dealmaking
2.1. Introduction
2.2. Obstetrics partnering over the years
2.3. Bigpharma obstetrics dealmaking activity
2.4. Bigpharma not active in pediatrics 
2.5. Obstetrics partnering by deal type
2.6. Obstetrics partnering by industry sector
2.7. Obstetrics partnering by stage of development
2.8. Obstetrics partnering by technology type
2.9. Obstetrics partnering by obstetrics indication
2.10. Average deal terms for obstetrics
2.10.1 Obstetrics headline values 
2.10.2 Obstetrics upfront payments 
2.10.3 Obstetrics milestone payments
2.10.4 Obstetrics royalty rates
 
Chapter 3 – Leading obstetrics deals
3.1. Introduction
3.2. Top obstetrics deals by value
3.3. Top obstetrics deals involving bigpharma
 
Chapter 4 – Bigpharma obstetrics deals
4.1. Introduction
4.2. How to use bigpharma partnering deals
4.3. Bigpharma obstetrics partnering company profiles
Abbott
Allergan
AstraZeneca 
Baxter International
Biogen Idec 
Bristol-Myers Squibb
Daiichi Sankyo
Eisai 
Forest Laboratories
GlaxoSmithKline
Johnson & Johnson
Merck & Co 
Merck KGaA 
Mitsubishi Tanabe
Novartis 
Novo Nordisk 
Pfizer 
Roche 
Sanofi 
Shionogi
Teva
 
Chapter 5 – Obstetrics partnering contracts directory 
5.1. Introduction 
5.2. By deal type 
Collaborative R&D 
Contract service 
Co-promotion 
Development 
Distribution 
Licensing 
Manufacturing 
Marketing 
Option 
Promotion 
Research 
Supply 
5.3. By stage of development
Discovery 
Preclinical 
Phase I 
Phase III 
Marketed 
5.4. By technology type 
Assays 
Biological compounds 
Discovery tools 
Drug delivery 
Genomics 
Natural product 
Orphan drug 
Peptides 
Screening 
Small molecules 
 
Chapter 6 – Obstetrics dealmaking by indication
6.1. Introduction 
 
Chapter 7 – Partnering resource center
7.1. Online partnering 
7.2. Partnering events 
7.3. Further reading on dealmaking
 
Appendices 
Appendix 1 – Directory of obstetrics deals by company A-Z 2007-2012
Appendix 2 – Directory of obstetrics deals by deal type 2007-2012
Appendix 3 – Directory of obstetrics deals by stage of development 2007-2012
Appendix 4 – Directory of obstetrics deals by technology type 2007-2012 
Appendix 5 – Deal type definitions

List of Chart


Figure 1: Obstetrics partnering since 2009
Figure 2: Bigpharma – top 50 – obstetrics deals 2007 to 2012
Figure 3: Bigpharma obstetrics deal frequency – 2007 to 2012
Figure 4: Inactive bigpharma in obstetrics 2007-2012
Figure 5: Obstetrics partnering by deal type since 2009 
Figure 6: Obstetrics partnering by industry sector since 2009 
Figure 7: Obstetrics partnering by stage of development since 2009
Figure 8: Obstetrics partnering by technology type since 2009 
Figure 9: Obstetrics partnering by target since 2009 
Figure 10: Obstetrics deals with a headline value
Figure 11: Obstetrics deal headline value distribution, US$million – discovery stage 
Figure 12: Obstetrics deal headline value distribution, US$million – preclinical stage 
Figure 13: Obstetrics deal headline value distribution, US$million – phase I stage 
Figure 14: Obstetrics deal headline value distribution, US$million – phase II stage 
Figure 15: Obstetrics deal headline value distribution, US$million – phase III stage 
Figure 16: Obstetrics deal headline value distribution, US$million – regulatory stage 
Figure 17: Pediatrics deal headline value distribution, US$million – marketed stage 
Figure 18: Summary median headline value by stage of development, 2007-2012 
Figure 19 Obstetrics deals with upfront payment values 
Figure 20: Obstetrics deal upfront payment distribution, US$million – discovery stage 
Figure 21: Obstetrics deal upfront payment distribution, US$million – preclinical stage 
Figure 22: Obstetrics deal upfront payment distribution, US$million – phase I stage 
Figure 23: Obstetrics deal upfront payment distribution, US$million – phase II stage
Figure 24: Obstetrics deal upfront payment distribution, US$million – phase III stage
Figure 25: Obstetrics deal upfront payment distribution, US$million – regulatory stage 
Figure 26: Obstetrics deal upfront payment distribution, US$million – marketed stage 
Figure 27: Summary median upfront payments by stage of development, 2007-2012 
Figure 28: Obstetrics deals with milestone payments 
Figure 29: Obstetrics deal milestone distribution, US$million – discovery stage 
Figure 30: Obstetrics deal milestone distribution, US$million – preclinical stage
Figure 31: Obstetrics deal milestone distribution, US$million – phase I stage 
Figure 32: Obstetrics deal milestone distribution, US$million – phase II stage 
Figure 33: Obstetrics deal milestone distribution, US$million – phase III stage 
Figure 34: Obstetrics deal milestone distribution, US$million – regulatory stage
Figure 35: Obstetrics deal milestone distribution, US$million – marketed stage 
Figure 36: Obstetrics health deals with royalty rates, % 
Figure 37: Obstetrics deal royalty rate distribution, US$million – discovery stage
Figure 38: Obstetrics deal royalty rate distribution, US$million – preclinical stage
Figure 39: Obstetrics deal royalty rate distribution, US$million – phase I stage
Figure 40: Obstetrics deal royalty rate distribution, US$million – phase II stage
Figure 41: Obstetrics deal royalty rate distribution, US$million – phase III stage
Figure 42: Obstetrics deal royalty rate distribution, US$million – regulatory stage
Figure 44: Summary median royalty rate by stage of development, 2007-2012
Figure 45: Top obstetrics deals by value since 2009 
Figure 46: Top obstetrics deals signed by bigpharma value since 2009 
Figure 47: Online partnering resources 
Figure 48: Forthcoming partnering events

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *